Targeting the chemokines in cardiac repair

Current Pharmaceutical Design

Volumn 20, Issue 12, 2014, Pages 1971-1979

  Cavalera, Michele ^a   Frangogiannis, Nikolaos G ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac remodeling; Chemokine; Cytokine; Fibrosis; Leukocyte; Monocyte chemoattractant protein 1; Myocardial infarction

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CD11B ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR CCR2; COMPLEMENT MEMBRANE ATTACK COMPLEX; CX3C CHEMOKINE; FIBROBLAST GROWTH FACTOR 2; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GLUTAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEONECTIN; OSTEOPONTIN; RANTES; REACTIVE OXYGEN METABOLITE; STROMAL CELL DERIVED FACTOR 1; TENASCIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIAC REPAIR; CELLS; CHEMOTAXIS; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LEUKOCYTE ACTIVATION; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGENERATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; TRENDS;

ANIMALS; CHEMOKINE CXCL12; CHEMOKINES; CHEMOKINES, CXC; DRUG DELIVERY SYSTEMS; HUMANS; MYOCARDIAL INFARCTION;

EID: 84898635994     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990449     Document Type: Article

References (99)

1. Jennings RB, Murry CE, Steenbergen C, Jr., Reimer KA. Development of cell injury in sustained acute ischemia. Circulation 1990; 82: II2-II12.
2. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wave-front phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977; 56: 786-794.
3. Frangogiannis NG. The mechanistic basis of infarct healing. Anti-oxid Redox Signal 2006; 8: 1907-1939.
4. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012; 110: 159-173.
5. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost 2007; 97: 738-747.
6. Clark-Lewis I, Kim KS, Rajarathnam K, et al. Structure-activity relationships of chemokines. J Leukoc Biol 1995; 57: 703-711.
7. Zlotnik A, Morales J, Hedrick JA. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 1999; 19: 1-47.
8. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858-864.
9. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-115.
10. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127.
11. Lakshminarayanan V, Lewallen M, Frangogiannis NG, et al. Reac tive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am J Pathol 2001; 159: 1301-1311.
12. Nossuli TO, Frangogiannis NG, Knuefermann P, et al. Brief mur-ine myocardial I/R induces chemokines in a TNF-alpha-independent manner: role of oxygen radicals. Am J Physiol Heart Circ Physiol 2001; 281: H2549-H2558.
13. Hill JH, Ward PA. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971; 133: 885-900.
14. Kilgore KS, Park JL, Tanhehco EJ, Booth EA, Marks RM, Luc-chesi BR. Attenuation of interleukin-8 expression in C6-deficient rabbits after myocardial ischemia/reperfusion. J Mol Cell Cardiol 1998; 30: 75-85.
15. Oyama J, Blais C, Jr., Liu X, et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004; 109: 784-789.
16. Arslan F, Smeets MB, O'Neill LA, et al. Myocardial ische-mia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010; 121: 80-90.
17. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardio-vasc Res 2006; 72: 384-393.
18. McKee CM, Penno MB, Cowman M, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macro-phages. The role of HA size and CD44. J Clin Invest 1996; 98: 2403-2413.
19. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate dermal endothelial recognition of injury through TLR4. J Biol Chem 2004.
20. Taylor KR, Trowbridge JM, Rudisill JA, Termeer CC, Simon JC, Gallo RL. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004; 279: 17079-17084.
21. Maekawa N, Wada H, Kanda T, et al. Improved myocardial ische-mia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J Am Coll Cardiol 2002; 39: 1229-1235.
22. Bujak M, Dobaczewski M, Chatila K, et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 2008; 173: 57-67.
23. Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ische-mia/reperfusion injury. Circulation 2011; 123: 594-604.
24. Mezzaroma E, Toldo S, Farkas D, et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A 2011; 108: 19725-19730.
25. Frangogiannis NG, Lindsey ML, Michael LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation 1998; 98: 699-710.
26. Somasundaram P, Ren G, Nagar H, et al. Mast cell tryptase may modulate endothelial cell phenotype in healing myocardial infarcts. J Pathol 2005; 205: 102-111.
27. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 2011; 108: 1122-1132.
28. Stancovski I, Baltimore D. NF-kappaB activation: the I kappaB kinase revealed? Cell 1997; 91: 299-302.
29. Zeilhofer HU, Schorr W. Role of interleukin-8 in neutrophil signaling. Curr Opin Hematol 2000; 7: 178-182.
30. Kukielka GL, Smith CW, LaRosa GJ, et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest 1995; 95: 89-103.
31. Ivey CL, Williams FM, Collins PD, Jose PJ, Williams TJ. Neutro-phil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8. J Clin Invest 1995; 95: 2720-2728.
32. Chandrasekar B, Smith JB, Freeman GL. Ischemia-reperfusion of rat myocardium activates nuclear factor-KappaB and induces neu-trophil infiltration via lipopolysaccharide-induced CXC chemokine. Circulation 2001; 103: 2296-2302.
33. Tarzami ST, Miao W, Mani K, et al. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation 2003; 108: 2387-2392.
34. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-27357.
35. Strieter RM, Polverini PJ, Arenberg DA, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol 1995; 57: 752-762.
36. Frangogiannis NG, Mendoza LH, Lewallen M, Michael LH, Smith CW, Entman ML. Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. FASEB J 2001; 15: 1428-1430.
37. Bujak M, Dobaczewski M, Gonzalez-Quesada C, et al. Induction of the CXC chemokine interferon-gamma-inducible protein 10 regulates the reparative response following myocardial infarction. Circ Res 2009; 105: 973-983.
38. Zaruba MM, Franz WM. Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy. Expert Opin Biol Ther 2010; 10: 321-335.
39. Askari AT, Unzek S, Popovic ZB, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362: 697-703.
40. Frangogiannis NG. The stromal cell-derived factor-1/CXCR4 axis in cardiac injury and repair. J Am Coll Cardiol 2011; 58: 2424-2426.
41. Pillarisetti K, Gupta SK. Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1)1: SDF-1 alpha mRNA is selectively induced in rat model of myocardial infarction. Inflammation 2001; 25: 293-300.
42. Saxena A, Fish JE, White MD, et al. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation 2008; 117: 2224-2231.
43. Zhang M, Mal N, Kiedrowski M, et al. SDF-1 expression by mes-enchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. Faseb J 2007; 21: 3197-3207.
44. Segers VF, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007; 116: 1683-1692.
45. Sasaki T, Fukazawa R, Ogawa S, et al. Stromal cell-derived factor-1alpha improves infarcted heart function through angiogenesis in mice. Pediatr Int 2007; 49: 966-971.
46. Hu X, Dai S, Wu WJ, et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation 2007; 116: 654-663.
47. Chen J, Chemaly E, Liang L, Kho C, Lee A, Park J, Altman P, Schecter AD, Hajjar RJ, Tarzami ST. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol 2010; 176: 1705-1715.
48. Dai S, Yuan F, Mu J, et al. Chronic AMD3100 antagonism of SDF-1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction. J Mol Cell Cardiol 2010; 49: 587-597.
49. Proulx C, El-Helou V, Gosselin H, et al. Antagonism of stromal cell-derived factor-1alpha reduces infarct size and improves ventricular function after myocardial infarction. Pflugers Arch 2007; 455: 241-250.
50. Jujo K, Hamada H, Iwakura A, et al. CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci U S A 2010; 107: 11008-11013.
51. Liehn EA, Tuchscheerer N, Kanzler I, et al. Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol 2011; 58: 2415-2423.
52. Agarwal U, Ghalayini W, Dong F, et al. Role of cardiac myocyte CXCR4 expression in development and left ventricular remodeling after acute myocardial infarction. Circ Res 2010; 107: 667-676.
53. Kumar AG, Ballantyne CM, Michael LH, et al. Induction of mono-cyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardium. Circulation 1997; 95: 693-700.
54. Ono K, Matsumori A, Furukawa Y, et al. Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemo-tactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1999; 79: 195-203.
55. Kakio T, Matsumori A, Ono K, Ito H, Matsushima K, Sasayama S. Roles and relationship of macrophages and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the ischemic and reperfused rat heart. Lab Invest 2000; 80: 1127-1136.
56. Tarzami ST, Cheng R, Miao W, Kitsis RN, Berman JW. Chemokine expression in myocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomyocytes from cell death. J Mol Cell Cardiol 2002; 34: 209-221.
57. Dewald O, Ren G, Duerr GD, et al. Of mice and dogs: species-specific differences in the inflammatory response following myo-cardial infarction. Am J Pathol 2004; 164: 665-677.
58. Dewald O, Zymek P, Winkelmann K, et al. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005; 96: 881-889.
59. Kaikita K, Hayasaki T, Okuma T, Kuziel WA, Ogawa H, Takeya M. Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol 2004; 165: 439-447.
60. Hayashidani S, Tsutsui H, Shiomi T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003; 108: 2134-2140.
61. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204: 3037-3047.
62. Frangogiannis NG, Dewald O, Xia Y, et al. Critical role of mono-cyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 2007; 115: 584-592.
63. Liehn EA, Piccinini AM, Koenen RR, et al. A new monocyte che-motactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J Am Coll Cardiol 2010; 56: 1847-1857.
64. Ban K, Ikeda U, Takahashi M, Kanbe T, Kasahara T, Shimada K. Expression of intercellular adhesion molecule-1 on rat cardiac myocytes by monocyte chemoattractant protein-1. Cardiovasc Res 1994; 28: 1258-1262.
65. Zhou L, Azfer A, Niu J, et al. Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res 2006; 98: 1177-1185.
66. Bidzhekov K, Zernecke A, Weber C. MCP-1 induces a novel transcription factor with proapoptotic activity. Circ Res 2006; 98: 1107-1109.
67. Schenk S, Mal N, Finan A, et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007; 25: 245-251.
68. Bousquenaud M, Schwartz C, Leonard F, et al. Monocyte chemo-tactic protein 3 is a homing factor for circulating angiogenic cells. Cardiovasc Res 2012; 94: 519-525.
69. Westermann D, Savvatis K, Lindner D, et al. Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopa-thy. Circulation 2011; 124: 2082-2093.
70. Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol 1995; 25: 64-68.
71. Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas SM, Kremastinos DT. Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res 2002; 22: 223-229.
72. Montecucco F, Braunersreuther V, Lenglet S, et al. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J 2012; 33: 1964-1974.
73. Flierl U, Schafer A. Fractalkine--a local inflammatory marker aggravating platelet activation at the vulnerable plaque. Thromb Haemost 2012; 108: 457-463.
74. Xuan W, Liao Y, Chen B, et al. Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res 2011; 92: 385-393.
75. Husberg C, Nygard S, Finsen AV, et al. Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. J Mol Cell Cardiol 2008; 45: 261-269.
76. Frangogiannis NG, Mendoza LH, Lindsey ML, et al. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J Immunol 2000; 165: 2798-2808.
77. Yang Z, Zingarelli B, Szabo C. Crucial role of endogenous inter-leukin-10 production in myocardial ischemia/reperfusion injury. Circulation 2000; 101: 1019-1026.
78. Zymek P, Nah DY, Bujak M, et al. Interleukin-10 is not a critical regulator of infarct healing and left ventricular remodeling. Cardio-vasc Res 2007; 74: 313-322.
79. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007; 74: 184-195.
80. Bassols A, Massague J. Transforming growth factor beta regulates the expression and structure of extracellular matrix chon-droitin/dermatan sulfate proteoglycans. J Biol Chem 1988; 263: 3039-3045.
81. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasmi-nogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol 1986; 103: 2403-2410.
82. Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 2011; 51: 600-606.
83. Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011; 17: 581-588.
84. Chen W, Saxena A, Li N, et al. Endogenous IRAK-M attenuates postinfarction remodeling through effects on macrophages and fi-broblasts. Arterioscler Thromb Vasc Biol 2012; 32: 2598-2608.
85. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and repara-tive response following myocardial infarction. J Mol Cell Cardiol 2010; 48: 504-511.
86. Dobaczewski M, de Haan JJ, Frangogiannis NG. The extracellular matrix modulates fibroblast phenotype and function in the infarcted myocardium. J Cardiovasc Transl Res 2012; 5: 837-847.
87. Huebener P, Abou-Khamis T, Zymek P, et al. CD44 Is Critically Involved in Infarct Healing by Regulating the Inflammatory and Fibrotic Response. J Immunol 2008; 180: 2625-2633.
88. Frangogiannis NG, Ren G, Dewald O, et al. The critical role of endogenous Thrombospondin (TSP)-1 in preventing expansion of healing myocardial infarcts. Circulation 2005; 111: 2935-2942.
89. Schellings MW, Vanhoutte D, Swinnen M, et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med 2009; 206: 113-123.
90. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012; 92: 635-688.
91. Cochain C, Auvynet C, Poupel L, et al. The chemokine decoy receptor D6 prevents excessive inflammation and adverse ventricular remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol 2012; 32: 2206-2213.
92. Dobaczewski M, Xia Y, Bujak M, Gonzalez-Quesada C, Fran-gogiannis NG. CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. Am J Pathol 2010; 176: 2177-2187.
93. Simpson PJ, Todd RF, 3rd, Fantone JC, et al. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest 1988; 81: 624-629.
94. Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recom-binant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001; 104: 2778-2783.
95. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002; 40: 1199-1204.
96. Armstrong PW, Granger CB, Adams PX, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. Jama 2007; 297: 43-51.
97. Briaud SA, Ding ZM, Michael LH, Entman ML, Daniel S, Ballan-tyne CM. Leukocyte trafficking and myocardial reperfusion injury in ICAM-1/P-selectin-knockout mice. Am J Physiol Heart Circ Physiol 2001; 280: H60-H67.
98. Gonzalez-Quesada C, Frangogiannis NG. Monocyte chemoattrac-tant protein-1/CCL2 as a biomarker in acute coronary syndromes. Current Atherosclerosis Reports 2009; 11: 131-138.
99. Frangogiannis NG. Biomarkers: hopes and challenges in the path from discovery to clinical practice. Transl Res 2012; 159: 197-204.